Articles tagged with Clinical Studies
Mount Sinai has launched an international clinical trial to determine the optimal treatment for spontaneous coronary artery dissection (SCAD), a sudden tear in the wall of a heart artery that can reduce blood flow and cause an uncommon type of heart attack. The trial, known as SCAD-ALIGN, will compare a moderate antiplatelet strategy o...
A new tool, INSPECT-SR, has been developed to assess the trustworthiness of randomized controlled trials (RCTs) and identify problematic studies. This tool, which has been endorsed by the Cochrane community, provides a rigorous and transparent method for reviewers to evaluate the integrity of trial data.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
Researchers tested a potential drug combination for metastatic uveal melanoma, uncovering clues about treatment resistance. The study found that levels of an enzyme called ALDH1A3 increased after treatment in patients whose disease progressed, while those whose disease remained stable had lower levels.
Researchers propose using carefully designed combinations of approved drugs to create a more convincing placebo, limiting participant disclosure, and rigorous testing to ensure effective masking. This approach, called UMBRAA, aims to overcome the challenge of distinguishing between psychedelic effects and the power of expectation.
A new brain-computer interface (BCI) allows people with vocal tract and bodily paralysis to convey both speech and upper-body gestures simultaneously. The BCI successfully translated the thoughts of patients into commands that dictated the expressions of a full-body virtual avatar.
Researchers found that fish serotonin transporters, similar to human counterparts, can be highly sensitive to antidepressants found in water, highlighting potential risks to aquatic life. The study suggests prioritizing specific pharmaceuticals in environmental monitoring programs and deriving species-specific risk thresholds.
Insilico Medicine has dosed the first patient in the GENESIS-IPF-3 Phase III clinical trial of Rentosertib, a generative AI-driven innovative drug for idiopathic pulmonary fibrosis. The 52-week trial aims to evaluate Rentosertib's efficacy and safety in a larger cohort of patients with IPF.
A clinical trial shows that laughter therapy can reduce breathing difficulties and is as effective as traditional breathing exercises in COPD patients. Patients who underwent laughter therapy had less difficulty breathing and better overall health compared to those who received traditional breathing exercises or no treatment.
A new study at the University of Oklahoma is testing an interactive app called Connect2Care to increase prostate cancer screening among Black men in Oklahoma. The app provides culturally tailored education, guides users through at-home PSA testing, and connects them with medical professionals.
A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
A clinical trial funded by NIH found that PAXLOVID does not improve Long COVID symptoms, but its extended duration did not cause serious side effects. The study recruited 959 patients and monitored symptoms over six months.
A phase 2 clinical trial found that a monoclonal antibody targeting interleukin-6 achieved sustained reductions in inflammation biomarkers for six months in patients with chronic kidney disease. The therapy, known as pacibekitug, was well-tolerated and showed favorable effects on additional biomarkers associated with cardiovascular risk.
The Alliance for Clinical Trials in Oncology has released a film highlighting the importance of clinical trials in cancer research, featuring the story of a lung cancer patient who participated in a trial. The film emphasizes the human element of research and explores how individual participation contributes to progress in cancer care.
Researchers at Charité report significant success in treating severe rheumatoid arthritis with CD19 CAR T cells, reducing disease activity and promoting sustained remission in patients. The treatment targets disease-driving B cells, allowing the immune system to reset and eliminate harmful antibodies.
A new research tool, PGS-TRI, analyzes family data to understand how genetics and environment contribute to autism risk. The tool provides a more precise look at how 'nature' and 'nurture' interact within families, allowing researchers to better understand the complex factors that shape a child's health.
This review explores the impact of tryptophan metabolism on female reproductive health, including ovarian function, fertility, and maternal-fetal health. It highlights the therapeutic potential of tryptophan metabolism in treating ovarian diseases and proposes dietary supplementation, modulation of the gut microbiota, and melatonin ant...
A new study by the University of Illinois Chicago found that time-restricted eating may be a safe and effective tool to control blood sugar levels in adults with Type 1 diabetes. The study, led by Krista Varady, showed a significant reduction in blood sugar levels after six months, with no increased risk of extreme highs or lows.
Professors Etienne Cavalier and Roland Chapurlat assume leadership as Co-Editors-in-Chief, bringing complementary expertise in laboratory science, translational research, and clinical investigation. They aim to build on the journal's strong foundations and further enhance its role in musculoskeletal research.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
A new study reveals that fluctuations in estrogen influence brain connections in rats, using a specialized imaging technique called magnetic resonance elastography (MRE). Researchers hope to translate the findings to humans, exploring how hormonal changes affect brain health in women, particularly during menopause.
A new book by University of Virginia Health System expert Daniel J. Cox outlines a practical alternative to medication for managing pre-diabetes and type 2 diabetes. The GEM program emphasizes smart eating, physical activity, and listening to the body to regulate blood sugar levels.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
A new study suggests that a video game designed to raise teens' awareness of mental health issues can reduce symptoms of depression on par with in-school programs. The game, PlaySmart, was played by 269 students for up to six weeks, with significant reductions in symptoms reported after only six weeks.
A new clinical trial at HonorHealth Research Institute uses a vaccine-based on immune system dendritic cells to fight advanced melanoma. The vaccine has shown promising results in treating refractory and unresectable cases of the disease, with a 10-fold increase in immune response.
The partnership aims to increase enrollment in clinical trials, making research opportunities more accessible to patients. UCCCC and Lilly will work together to open studies faster and connect more patients with research opportunities.
A new Cochrane review analyzed 11 studies involving 2,524 women undergoing embryo transfer, finding no reliable evidence that preparatory techniques improve IVF success rates. The techniques examined included straightening the utero-cervical angle and removing cervical mucus before transfer.
ISM8969/HT-001 is an orally available, brain-penetrant NLRP3 inhibitor with promising in vitro and in vivo profiles. The clinical trial aims to evaluate its safety, tolerability, and efficacy in patients with Parkinson's disease.
A pilot clinical trial of psilocybin-assisted therapy in veterans with severe PTSD found that 75% of participants were in remission one month after treatment, with no serious adverse events reported. The results suggest the protocol may be a game-changer for those struggling with treatment-resistant PTSD.
ISM6331, a novel pan-TEAD inhibitor, has received Fast Track Designation from the FDA for treating adult patients with unresectable malignant pleural mesothelioma. The treatment boasts synergistic anti-tumor effects and potential to overcome drug resistance as combination therapy.
The first patient has been enrolled in a global Phase 3 clinical trial evaluating Mocertatug Rezetecan, a novel B7-H4-targeted ADC, in platinum-resistant ovarian cancer. The study aims to determine whether this therapy can improve outcomes compared with standard chemotherapy.
A new study from Reichman University found that a short three-week digital training program improved motor function and brain activity in Parkinson's patients. The program, called DopApp, strengthened connectivity between brain regions responsible for movement and induced localized changes in neural circuits.
Exercise produces small improvements in pain and physical function for people with hip osteoarthritis, but those improvements may not be large enough to make a meaningful difference in daily life. Quality of life showed little to no improvement with exercise.
The Biggs Institute is leading a $2.5 million national, multi-site study to improve detection and diagnosis of dementia with Lewy bodies. The study will enroll 125 participants and evaluate multiple possible new tools and methods to accurately identify individuals who have accumulated abnormal alpha-synuclein in the brain.
A new cancer drug has shown promising results in a mesothelioma trial, controlling disease progression in 67% of patients. The drug targets the cancer's energy system by inhibiting a specific enzyme, causing oxidative stress that kills tumor cells.
A new study found that simple weekly electronic symptom check-ins with care teams significantly improves the quality of life for individuals undergoing treatment for advanced cancer. The benefits were notable among patient groups that historically faced barriers to care, including Black patients and those with less formal education.
A landmark study has shown that transplanting stem-cell derived dopamine progenitor cells into the brain is feasible and safe. Eight patients received the transplanted cell product, with no serious side effects observed during the first year of follow-up.
A randomized clinical trial found that acupuncture to the ear (auriculotherapy) reduced migraine pain and improved its impact on daily life. The treatment showed a statistically significant improvement in oxygenation levels in the brain, but not a difference between the auriculotherapy and sham groups.
The University of California, San Francisco is launching a novel clinical trial to test a combination of therapies for the most common form of Alzheimer's disease. The trial will enroll up to 825 participants and test drugs that target both amyloid and tau proteins, with the goal of slowing disease progression.
The FDA has granted early access to clinical trials for the new medication, allowing HonorHealth Research Institute to offer it to patients with previously treated metastatic pancreatic cancer. The drug has shown significant advancement in targeted therapy for pancreatic cancer, offering a median overall survival of 13.2 months.
Rentosertib is a potentially first-in-class oral small-molecule inhibitor targeting TNIK for the treatment of idiopathic pulmonary fibrosis. The Phase III clinical trial will evaluate the efficacy and safety of once-daily Rentosertib administered over 52 weeks.
Researchers will study blood samples and environmental exposures over 10 years to identify genetic, environmental, and cellular factors contributing to autoimmune diseases. The goal is to develop prevention strategies and treatments by understanding the earliest biological triggers of SARDs.
Researchers at the University of Calgary have developed a novel CAR T-cell therapy called GCAR1, showing strong preclinical and early clinical promise in treating sarcoma and other cancers. The therapy has been tested on two Canadian patients, with one patient experiencing significant prolongation of life expectancy by 18 months.
A large clinical trial found that an AI support tool improved the quality of clinical documentation and treatment planning, but did not significantly change short-term patient outcomes. The study involved over 9,600 patients in Kenya and used a randomized controlled design to test the effectiveness of the AI tool.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
A new study suggests that functional brain imaging can help guide accelerated transcranial magnetic stimulation (TMS) for depression, leading to improved symptoms and response rates. The approach uses resting-state functional connectivity analysis to identify individualized treatment targets.
Researchers at UCI Health have begun the world's first clinical trial for Huntington’s disease using neural stem cells. The phase 1b/2a trial aims to evaluate the safety and potential benefits of this innovative therapy, which could slow disease progression and reduce long-term care costs.
Researchers discovered Paneth cell metaplasia can act as a protective response in ulcerative colitis by promoting healing and regeneration of the intestinal lining through REG3A. However, persistent changes may still carry risks, including increased cancer risk.
Insilico Medicine has completed the first-in-human dosing of its AI-driven NLRP3 inhibitor ISM8969 in a Phase I clinical study. The trial aims to evaluate the safety, tolerability, and efficacy of ISM8969 in healthy participants and those at risk of cardiovascular disease.
Semmelweis University's new Anatomy & Innovation Center for Education and Research has hosted two NATO battlefield surgery courses, providing realistic environments for learning and practicing new procedures. The center aims to improve patient safety and quality of care through advanced technologies and hands-on training.
Dr. Jennifer Guida, a renowned researcher and program director, has been appointed as the first director of HonorHealth Research Institute's Division of Institutional Research. She will oversee the institute's clinical trials efforts, providing patients with pioneering treatments based on internal research discoveries.
The NOVO EXPENDITURE trial investigates the effects of a hormone-based treatment on weight loss compared to a reduced-calorie diet. Participants will undergo extensive physiological testing, including metabolic chamber sessions and regular weigh-ins, to assess the treatment's impact on energy use and body weight.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Klick Labs is launching a series of clinical studies with Mayo Clinic exploring the use of novel vocal biomarkers in connection with Type 2 diabetes, hypertension, ovulation, and blood glucose. The research collaboration aims to leverage the voice's hidden properties to flag critical health issues and enhance patient care.
A clinical trial tested four remote monitoring approaches against usual care and found that none outperformed usual care in reducing readmissions. The study highlights the importance of studying real-world care models to optimize outcomes.
The FDA has accepted Genentech's supplemental Biologic License Application for atezolizumab, supported by phase III ATOMIC trial results. The trial showed a 50% reduction in cancer recurrence or death and 86.3% disease-free survival rate.
A multinational clinical trial found that balanced crystalloid fluid and 0.9% saline are equally safe and effective for treating septic shock in children. The study enrolled over 9,000 children and showed no difference in outcomes between the two IV fluids.
Dr. Nageatte Ibrahim brings her expertise in immunotherapy and cancer drug development to HonorHealth Research Institute, focusing on advancing novel treatments and improving patient outcomes. The institute aims to develop collaborations with leading research centers worldwide to bring cutting-edge therapies to patients in need.
The FLOW trial shows that semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease. Health utility scores and self-rated general health scores improved with semaglutide, but declined with placebo.